Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Etomidate; Propofol

Criteria

Inclusion Criteria:

1. Adult patients (age ≥18 years old)

2. Having endoscopic procedure at CUH with anesthesia

3. ASA 3 or above

Exclusion Criteria:

1. Known allergies or adverse reactions to study drugs or study drug components or preservatives

2. Patient refusal

3. Clinician refusal

4. Documented cognitive impairments precluding subject ability to consent for themselves unless a surrogate documented legally acceptable decision maker consents for patient participation

5. Prisoner or incarcerated or patients held by law enforcement officials in custody

6. Pregnancy or patient refusal for pregnancy testing or screening (standard UTSW policy and protocol requires pregnancy testing for appropriate patients prior to anesthesia)